August 06, 2019
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
EMA validates abicipar marketing authorization application
The European Medicines Agency has validated the marketing authorization application for abicipar, Molecular Partners announced.
If approved, abicipar, a novel DARPin therapy for the treatment of wet age-related macular degeneration, would be the first anti-VEGF therapy to sustain vision gains on a fixed 12-week dosing interval, a press release said.
The validation allows a formal review process to begin.
Allergan, Molecular Partners’ strategic partner, submitted the application.